Zafereo, M., Wang, R. J., Busaidy, N. L., Dadu, R., Iyer, P. C., Waguespack, S. G., Xu, L., Maniakas, A., Banuchi, V., Lai, S. Y., Chinn, S. B., Geiger, J. L., Kerrigan, K. C., Khan, S. A., Moore, E. J., Ryder, M. M., Scharpf, J., Worden, F. P., Williams, M. D., Cabanillas, M. E. (2025). Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for
            <i>BRAF</i>
            V600E-mutated anaplastic thyroid cancer (
            <i>BRAF</i>
            m-ATC): A multicenter phase 2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6008